Further to DrugAlert volume 804, HPS Pharmacies wish to advise that suppliers are continuing to experience a supply interruption for amoxicillin + clavulanic acid 875mg/125mg tablets.
|Alphaclav Duo Forte||230396||Early November 2022|
|Amclavox Duo Forte||288119||Late November 2022|
|AmoxyClav Generichealth 875/125||255076||Late October 2022|
|APX-Amoxicillin/Clavulanic Acid 875/125||351833||Early December 2022|
|Augmentin Duo Forte||54900||Mid-September 2022|
|Curam Duo Forte||198109||Early October 2022|
This supply interruption is due to an unexpected increase in demand.
An internationally registered brand of amoxicillin + clavulanic acid 875mg/125mg tablets has been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates